Published in J Clin Microbiol on June 12, 2012
New Insights Regarding Yeast Survival following Exposure to Liposomal Amphotericin B. Antimicrob Agents Chemother (2015) 0.76
Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin. Front Microbiol (2016) 0.75
A Flow Cytometric and Computational Approaches to Carbapenems Affinity to the Different Types of Carbapenemases. Front Microbiol (2016) 0.75
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother (2003) 7.09
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat (2011) 3.40
Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother (1996) 3.40
Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother (2005) 2.62
Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol (2009) 2.40
Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents (2006) 1.77
Combinations of antifungal agents in therapy--what value are they? J Antimicrob Chemother (2004) 1.73
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother (2002) 1.70
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis (2011) 1.57
Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect (2001) 1.21
Rapid flow cytometric susceptibility testing of Candida albicans. J Clin Microbiol (1997) 1.20
Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect (2009) 1.17
Antifungal combination therapy: clinical potential. Drugs (2005) 1.16
Use of flow cytometric methods for single-cell analysis in environmental microbiology. Curr Opin Microbiol (2008) 1.11
Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother (2006) 1.04
Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents (2007) 1.01
Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother (2010) 0.95
Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy. J Med Microbiol (2001) 0.93
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother (2011) 0.93
Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans. J Clin Microbiol (2004) 0.91
In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J Infect Chemother (2009) 0.89
The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Curr Opin Infect Dis (2006) 0.88
Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation. Pediatr Transplant (2005) 0.86
Evaluation of antifungal susceptibility using flow cytometry. Methods Mol Biol (2010) 0.85
Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods. Antimicrob Agents Chemother (2008) 0.84
Antifungal susceptibility testing of Candida species by flow cytometry. J Korean Med Sci (1999) 0.83
Rapid flow-cytometric susceptibility testing of Candida species. J Antimicrob Chemother (2004) 0.82
In vitro interaction of micafungin and fluconazole against Candida. J Antimicrob Chemother (2007) 0.82
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents (2006) 0.81
Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates. Antimicrob Agents Chemother (2010) 0.81
In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. Antimicrob Agents Chemother (2008) 0.81
Experience with a mixed semantic/syntactic parser. Proc Annu Symp Comput Appl Med Care (1995) 5.61
A natural language understanding system combining syntactic and semantic techniques. Proc Annu Symp Comput Appl Med Care (1994) 3.42
Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis (2002) 3.04
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int (2008) 2.26
Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med (1989) 1.41
In vitro activity of ciprofloxacin against Brucella melitensis. Eur J Clin Microbiol (1984) 1.33
Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis (2005) 1.26
Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect (2001) 1.21
Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol (2000) 1.20
Cefotaxime breakpoint for Streptococcus pneumoniae. Antimicrob Agents Chemother (1993) 1.15
Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab (2004) 1.09
Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob Agents Chemother (2011) 1.06
A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect Dis (2008) 1.04
In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy (2001) 1.03
A novel flow cytometric assay for rapid detection of extended-spectrum beta-lactamases. Clin Microbiol Infect (2012) 1.02
Safe susceptibility testing of Mycobacterium tuberculosis by flow cytometry with the fluorescent nucleic acid stain SYTO 16. J Med Microbiol (2005) 1.01
Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother (2008) 0.98
Parasitologic and immunologic diagnosis of American (mucocutaneous) leishmaniasis. Bull Pan Am Health Organ (1981) 0.96
Antibacterial studies, DNA oxidative cleavage, and crystal structures of Cu(II) and Co(II) complexes with two quinolone family members, ciprofloxacin and enoxacin. J Inorg Biochem (2005) 0.96
In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter (2006) 0.95
Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: comparison with CLSI broth microdilution method. Antimicrob Agents Chemother (2006) 0.95
Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis (2014) 0.95
Antifungal activity of local anesthetics against Candida species. Infect Dis Obstet Gynecol (2000) 0.94
Comparison of different protocols for the extraction of microbial DNA from reef corals. Braz J Microbiol (2012) 0.93
Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins. Med Mycol (2010) 0.93
Susceptibility to fluconazole of Candida clinical isolates determined by FUN-1 staining with flow cytometry and epifluorescence microscopy. J Med Microbiol (2001) 0.93
Is the lack of concurrence of bacterial vaginosis and vaginal candidosis explained by the presence of bacterial amines? Am J Obstet Gynecol (1999) 0.92
Multiplex PCR identification of eight clinically relevant Candida species. Med Mycol (2007) 0.90
[Nephropathic cystinosis: report of 2 cases and review of the literature]. Rev Assoc Med Bras (1994) 0.89
Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis (2000) 0.89
Simple and highly discriminatory microsatellite-based multiplex PCR for Aspergillus fumigatus strain typing. Clin Microbiol Infect (2009) 0.89
Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus. J Chemother (1993) 0.89
Anti-Candida activity of essential oils. Mini Rev Med Chem (2009) 0.88
Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev (2001) 0.88
Cerium, chitosan and hamamelitannin as novel biofilm inhibitors? J Antimicrob Chemother (2012) 0.87
Simultaneous determination of aortic valve area by the Gorlin formula and by transesophageal echocardiography under different transvalvular flow conditions. Evidence that anatomic aortic valve area does not change with variations in flow in aortic stenosis. J Am Coll Cardiol (1997) 0.87
Intraphagocytic killing of gram-positive bacteria by ciprofloxacin. J Antimicrob Chemother (1994) 0.86
In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis. J Antimicrob Chemother (1994) 0.86
The anti-Candida activity of Thymbra capitata essential oil: effect upon pre-formed biofilm. J Ethnopharmacol (2012) 0.85
Granulomatous hypersensitivity to Schistosoma mansoni egg antigens in human schistosomiasis. III. In vitro granuloma modulation induced by immune complexes. Am J Trop Med Hyg (1991) 0.85
Antioxidants in medicinal plant extracts. A research study of the antioxidant capacity of Crataegus, Hamamelis and Hydrastis. Phytother Res (2000) 0.84
[Parasitologic and immunologic diagnosis of American cutaneous leishmaniasis]. Bol Oficina Sanit Panam (1980) 0.84
Identification of pathogenic yeast species by polymerase chain reaction amplification of the RPS0 gene intron fragment. J Appl Microbiol (2009) 0.83
Anti-Candida activity of a chitosan hydrogel: mechanism of action and cytotoxicity profile. Gynecol Obstet Invest (2010) 0.83
[Study of in vitro activity of caspofungin on non-Candida albicans yeast strains determined by two methods: M27-A2 and EUCAST]. Rev Esp Quimioter (2004) 0.83
Mechanisms of action of quinolones against staphylococci and relationship with their in vitro bactericidal activity. Chemotherapy (1999) 0.83
Voriconazole inhibits biofilm formation in different species of the genus Candida. J Antimicrob Chemother (2012) 0.83
Candida balanitis: risk factors. J Eur Acad Dermatol Venereol (2009) 0.83
In vivo antibiofilm effect of cerium, chitosan and hamamelitannin against usual agents of catheter-related bloodstream infections. J Antimicrob Chemother (2012) 0.82
In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One. Mycoses (2006) 0.82
Inhibition of germ tube formation by Candida albicans by local anesthetics: an effect related to ionic channel blockade. Curr Microbiol (2000) 0.82
Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. J Hypertens (2001) 0.81
Anti-biofilm activity of low-molecular weight chitosan hydrogel against Candida species. Med Microbiol Immunol (2013) 0.81
[Effect of fluconazole and itraconazole on human polymorphonuclear leukocyte oxidative metabolism and phagocytosis]. Rev Esp Quimioter (1998) 0.80
Measurement of relative antioxidant activity of compounds: a methodological note. Redox Rep (1999) 0.80
Granulomatous hypersensitivity to Schistosoma mansoni egg antigens in human schistosomiasis. II. In vitro granuloma modulation induced by polyclonal idiotypic antibodies. J Immunol (1991) 0.80
Polyethyleneimine and polyethyleneimine-based nanoparticles: novel bacterial and yeast biofilm inhibitors. J Med Microbiol (2014) 0.80
Chemical composition and antifungal activity of the essential oil of Origanum virens on Candida species. Planta Med (2003) 0.80
Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis (2002) 0.79
The relationship between Candida species charge density and chitosan activity evaluated by ion-exchange chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.79
Synthesis, characterization, and crystal structure of [Cu(cinoxacinate)2].2H2O complex: a square-planar CuO4 chromophore. Antibacterial studies. J Inorg Biochem (1995) 0.79
Candida albicans fibrinogen binding mannoprotein: expression in clinical strains and immunogenicity in patients with candidiasis. Int Microbiol (1998) 0.79
The lactate minimum test protocol provides valid measures of cycle ergometer VO(2)peak. J Sports Med Phys Fitness (2003) 0.78
Laparoscopy and septic dissemination caused by perioperative perforation of the occluded small bowel: an experimental study. Surg Laparosc Endosc (1997) 0.78
Germ tube formation changes surface hydrophobicity of Candida cells. Infect Dis Obstet Gynecol (1999) 0.78
[Activity of itraconazole against clinical isolates of Aspergillus spp. and Fusarium spp. determined by the M38-P NCCLS method]. Rev Esp Quimioter (2001) 0.78
Cinoxacin complexes with divalent metal ions. Spectroscopic characterization. Crystal structure of a new dinuclear Cd(II) complex having two chelate-bridging carboxylate groups. Antibacterial studies. J Inorg Biochem (1998) 0.78
A novel flow cytometric protocol for assessment of yeast cell adhesion. Cytometry A (2011) 0.78
Chemical composition and antifungal activity of the essential oil of Thymbra capitata. Planta Med (2004) 0.78
Detection of Escherichia coli O157 by peptide nucleic acid fluorescence in situ hybridization (PNA-FISH) and comparison to a standard culture method. Appl Environ Microbiol (2013) 0.78
A new method for the detection of Pneumocystis jirovecii using flow cytometry. Eur J Clin Microbiol Infect Dis (2010) 0.77
C Reactive protein and disease severity in bronchiolitis. Rev Port Pneumol (2009) 0.77
Candida krusei reservoir in a neutropaenia unit: molecular evidence of a foe? Clin Microbiol Infect (2011) 0.77
[In vitro activity of voriconazole against yeast and algae isolates according to new resistance pattern cut-off points]. Rev Esp Quimioter (2006) 0.77
5C.05: DIFFERENCES IN PREVALENCE, AWARENESS, TREATMENT AND CONTROL RATES OF HYPERTENSION BETWEEN MALE AND FEMALE. J Hypertens (2015) 0.77
In vitro assessment of gentian violet anti- candida activity. Gynecol Obstet Invest (2012) 0.76